Adult patients with LVAD implantation
Conditions
Interventions
Apply platelet rich plasma to a commercially available antimicrobial wound dressing/protective material (such as Aquacel Ag) and applied, or applied directly to the wound and wound dressing/protective
Sponsors
miyagawa shigeru
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with delayed wound healing at the site of driveline insertion in patients with left ventricular assist devices(LVAD) 2) Patients who are able to have blood drawn for platelet rich plasma production. 3) Patients who have given their written consent prior to the collection of blood for the production of platelet rich plasma.
Exclusion criteria
Exclusion criteria: 1) Patients with thrombocytopenia 2) Patients with hematological malignancies such as aplastic anemia and leukemia 3) Patients with significant anemia (Hb less than 7g/dL for both sexes) 4) Patients whose symptoms may be aggravated by the administration of polyplatelet plasma 5) Patients who are hypersensitive or have an allergic reaction to sodium carboxymethylcellulose silver 6) Patients who are unable to follow the doctor's instructions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of cases and incidences of safety. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of patients with wound size reduction >50% before and 4 weeks after last dose 2. Percent reduction in wound size before and 1 week after treatment for each patient 3. Changes in effusion and infection/inflammation | — |
Countries
Japan
Contacts
Public Contacttakuji kawamura
Osaka University Hospital
Outcome results
None listed